Literature DB >> 12567188

The codon 72 polymorphic variants of p53 have markedly different apoptotic potential.

Patrick Dumont1, J I-Ju Leu, Anthony C Della Pietra, Donna L George, Maureen Murphy.   

Abstract

The gene TP53, encoding p53, has a common sequence polymorphism that results in either proline or arginine at amino-acid position 72. This polymorphism occurs in the proline-rich domain of p53, which is necessary for the protein to fully induce apoptosis. We found that in cell lines containing inducible versions of alleles encoding the Pro72 and Arg72 variants, and in cells with endogenous p53, the Arg72 variant induces apoptosis markedly better than does the Pro72 variant. Our data indicate that at least one source of this enhanced apoptotic potential is the greater ability of the Arg72 variant to localize to the mitochondria; this localization is accompanied by release of cytochrome c into the cytosol. These data indicate that the two polymorphic variants of p53 are functionally distinct, and these differences may influence cancer risk or treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12567188     DOI: 10.1038/ng1093

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  440 in total

Review 1.  Single-nucleotide polymorphisms in the p53 signaling pathway.

Authors:  Lukasz F Grochola; Jorge Zeron-Medina; Sophie Mériaux; Gareth L Bond
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-12-09       Impact factor: 10.005

Review 2.  The role of p53 gene family in reproduction.

Authors:  Wenwei Hu
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-28       Impact factor: 10.005

3.  Functional analysis of the p53 codon 72 polymorphism in black South Africans with rheumatoid arthritis--a pilot study.

Authors:  Devapregasan Moodley; Girish M Mody; Anil A Chuturgoon
Journal:  Clin Rheumatol       Date:  2010-06-10       Impact factor: 2.980

4.  WDR36 and P53 gene variants and susceptibility to primary open-angle glaucoma: analysis of gene-gene interactions.

Authors:  Cristina Blanco-Marchite; Francisco Sánchez-Sánchez; María-Pilar López-Garrido; Mercedes Iñigez-de-Onzoño; Francisco López-Martínez; Enrique López-Sánchez; Lydia Alvarez; Pedro-Pablo Rodríguez-Calvo; Carmen Méndez-Hernández; Luis Fernández-Vega; Julián García-Sánchez; Miguel Coca-Prados; Julián García-Feijoo; Julio Escribano
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-10-31       Impact factor: 4.799

5.  The association between polymorphism of P53 Codon72 Arg/Pro and hepatocellular carcinoma susceptibility: evidence from a meta-analysis of 15 studies with 3,704 cases.

Authors:  Surong Hu; Lianying Zhao; Jingting Yang; Miao Hu
Journal:  Tumour Biol       Date:  2013-12-11

6.  Lack of association of the TP53 Arg72Pro SNP and the MDM2 SNP309 with systemic lupus erythematosus in Caucasian, African American, and Asian children and adults.

Authors:  K B Onel; D Huo; D Hastings; J Fryer-Biggs; M K Crow; K Onel
Journal:  Lupus       Date:  2009-01       Impact factor: 2.911

7.  Gene polymorphisms predict toxicity to neoadjuvant therapy in patients with rectal cancer.

Authors:  Marjun P Duldulao; Wendy Lee; Rebecca A Nelson; Joyce Ho; Maithao Le; Zhenbin Chen; Wenyan Li; Joseph Kim; Julio Garcia-Aguilar
Journal:  Cancer       Date:  2012-10-23       Impact factor: 6.860

8.  Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation.

Authors:  Tsuyoshi Akagi; Ken Sasai; Hidesaburo Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

9.  TP53 Polymorphism Contributes to the Susceptibility to Bipolar Disorder but Not to Schizophrenia in the Chinese Han Population.

Authors:  Jialei Yang; Xulong Wu; Jiao Huang; Zhaoxia Chen; Guifeng Huang; Xiaojing Guo; Lulu Zhu; Li Su
Journal:  J Mol Neurosci       Date:  2019-05-05       Impact factor: 3.444

Review 10.  The genomic landscape of retinoblastoma: a review.

Authors:  Brigitte L Thériault; Helen Dimaras; Brenda L Gallie; Timothy W Corson
Journal:  Clin Exp Ophthalmol       Date:  2013-05-22       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.